✦ LIBER ✦

PCN37 A Pharmacoeconomic Analysis of the Implementation of Gefitinib in the Treatment of Metastasized Non-Small Cell Lung Cancer (NSCLC) With Proven EGFR-TK Mutations

✍ Scribed by J. Culig; M. Leppée; N. Skaron-Jakobovic

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

25 Gefitinib in the treatment of non-sma

✍ Nugent, L.; Das, T.; Mohanamurali, J.; Danson, S.J.; Fisher, P.M.; Hatton, M.Q.; 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 43 KB

PCN77 PHARMACOECONOMIC ANALYSIS OF ERLOT

✍ O Batigun; E Yildirim 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 75 KB

PCN63 EPIDERMAL GROWTH FACTOR RECEPTOR (

✍ G. de Lima Lopes 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 57 KB

Gefitinib in the treatment of elderly pa

✍ Bearz, Alessandra; Fratino, Lucia; Spazzapan, Simon; Berretta, Massimiliano; Gia 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 103 KB

PCN7 THE LIFETIME COST OF GEFITINIB (“IR

✍ A Haiderali; W Chin 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 63 KB

PCN75 COST-EFFECTIVENESS ANALYSIS OF EGF

✍ O Arrieta; P Anaya; RJ López; AC Polanco 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 95 KB